The adipose stromal cells play an important role in protecting and potentiating oncolytic viruses, as have been demonstrated in Calidi Biotherapeutics pre-clinical research with the oncolytic vaccinia virus.
Calidi Biotherapeutics has a robust intellectual property portfolio around its proprietary cell-based carrier system designed to overcome the challenge of effective delivery of oncolytic viruses while providing better treatments with minimal toxicity and improved efficacy. The portfolio consists of one granted patent and over 13 patent applications worldwide.
Our patent strategy will continue to help Calidi Biotherapeutics expand and protect our cell-based delivery platforms as we grow and expand our product candidates. These patents represent the culmination of our research and hard work discovering how to potentiate oncolytic virus treatments for cancer.